11 completed, 4 active not recruiting, 3 terminated, 2 withdrawn. 10 Phase 3, 6 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Active not recruiting 4, Completed 3, Withdrawn 2, Terminated 1 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow EyePoint Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME EYP-1901, Aflibercept (2.0 mg) - Diabetic Macular Edema, DME | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 240 | 2026-02-16 | 2026-10-02 |
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME EYP-1901, Aflibercept (2.0 mg) - Diabetic Macular Edema, DME | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 240 | 2026-02-09 | 2026-10-02 |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 EYP-1901, Aflibercept (2.0 mg) - Wet Age Related Macular Degeneration, wAMD | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 400 | 2024-11-27 | 2026-09-03 |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 EYP-1901, Aflibercept (2.0 mg) - Wet Age Related Macular Degeneration, wAMD | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 400 | 2024-10-22 | 2026-09-03 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph - Diabetic Macular Edema | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 27 | 2024-01-15 | 2025-03-04 |
| Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) EYP-1901, Sham IVT - Nonproliferative Diabetic Retinopathy | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 77 | 2022-09-28 | 2025-08-15 |
| A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) Dexycu, Placebo/Vehicle - Cataract | Phase 3 | Withdrawn | EyePoint Pharmaceuticals, Inc. | 2022-09-01 | 2024-04-03 | |
| A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery Dexycu, Placebo/Vehicle - Cataract | Phase 3 | Withdrawn | EyePoint Pharmaceuticals, Inc. | 2022-09-01 | 2025-08-11 | |
| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph - Wet Age-related Macular Degeneration | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 161 | 2022-06-30 | 2025-10-15 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract Dexamethasone, Prednisolone Acetate Ophthalmic - Cataract | Phase 4 | Terminated | EyePoint Pharmaceuticals, Inc. | 17 | 2022-01-04 | 2026-10-05 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) EYP-1901 - Wet Age-related Macular Degeneration | Phase 1 | Completed | EyePoint Pharmaceuticals, Inc. | 17 | 2021-01-20 | 2023-07-19 |
| Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution - COVID-19, Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Terminated | EyePoint Pharmaceuticals, Inc. | 31 | 2020-10-21 | 2023-06-08 |
| Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma Latanoprost ophthalmic solution, AKB-9778 4%, Placebo - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 194 | 2020-06-06 | 2023-05-25 |
| "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation" Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID) - Cataract | Phase 4 | Completed | The Eye Institute of West Florida | 25 | 2020-02-20 | 2025-02-25 |
| DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001 DEXYCU (dexamethasone intraocular suspension) 9%. - Cataract | Completed | EyePoint Pharmaceuticals, Inc. | 527 | 2019-11-13 | 2021-05-26 | |
| The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) AKB-9778, Placebo - Nonproliferative Diabetic Retinopathy | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 167 | 2017-06-09 | 2023-06-27 |
| Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter - Non-Infectious Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 26 | 2016-02-23 | 2020-05-01 |
| Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Sham Injection, FAI Insert - Posterior Uveitis, Intermediate Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 153 | 2015-06-02 | 2020-07-21 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert FAI insert, Sham injection - Non-Infectious Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 129 | 2013-08-02 | 2021-04-02 |
Cataract (5) · Uveitis, Intermediate (2) · Uveitis, Posterior (2) · COVID-19 (1) · Glaucoma, Open-Angle (1) · Ocular Hypertension (1) · Panuveitis (1) · Respiratory Distress Syndrome (1) · Uveitis (1)
aflibercept (6) · Calcium Dobesilate (4) · Bulk Drugs (2) · Fluocinolone Acetonide (2) · salicylhydroxamic acid (2) · vorolanib (2) · AKB-9778 (1) · Anti-Bacterial Agents (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Dexamethasone (1) · Solutions (1) · Steroids (1)
United States (17) · Germany (4) · Hungary (3) · India (3) · Israel (3) · Brazil (2) · Czechia (2) · Poland (2) · Slovakia (2) · United Kingdom (2)
Flavio Leonin Jr., MD (2) · Dario Paggiarino, MD (1) · Flavio Leonin, Jr., MD (1) · Gerard E Riedel, PhD (1) · Glenn Jaffe, MD (1) · Keyur Patel, PharmD (1) · Paul Ashton, PhD (1) · Ramiro Ribeiro, MD (1) · Ramiro Ribeiro, MD, PhD (1) · Robert J Weinstock, MD (1)